Sweden · Delayed Price · Currency is SEK Fluicell AB Company Description
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden.
The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.
It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet.
Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.
| Country | Sweden |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Carolina Trjulja |
Contact Details
Address: Flöjelbergsgatan 8C Mölndal, 431 37 Sweden | |
| Phone | 46 735 14 09 91 |
| Website | fluicell.com |
Stock Details
| Ticker Symbol | FLUI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010831321 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Carolina Trjulja | Chief Executive Officer |
| Gavin D. M. Jeffries | Co-Founder, Chief Technology Officer and Director |
| Joakim Wahlberg | Chief Financial Officer |
| Jonas Hannestad | Chief Marketing and Communications Officer |